Outcomes16

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 16 of 16

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26	Week 26	Any patent who received drug	10^9 platelets/L	MEDIAN
SECONDARY	Safety as Measured by Incidences of Adverse Events, Vital Signs, ECG, and Clinical Laboratory Tests	Pre-dose and up to 771 days post-dose	The safety population includes all participants who received any amount of study drug.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Thrombotic Microangiopathies (TMA) Response	26 weeks	Any patient who received drug	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	TMA Event-free Status	26 weeks	Any patient who received drug	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Increase in Estimated Glomerular Filtration Rate (eGFR)	26 weeks	Any patient who received drug	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Hematological Normalization	26 weeks	Any patient who received drug	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	TMA Remission	26 weeks	Any patient who received drug	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Incidence of Antidrug Antibodies (ADA)	771 days post-dose	Any patient who received drug	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Change From Baseline in Serum Creatinine (mg/dL)	26 weeks	Any patient who received drug	mg/dL	MEDIAN
SECONDARY	Change From Baseline in Serum LDH (U/L)	26 weeks	Any patient who received drug.	U/L	MEDIAN
SECONDARY	Change From Baseline in Haptoglobin (mg/dL)	26 weeks	Any patient who received drug.	mg/dL	MEDIAN
SECONDARY	Pharmacokinetics (PK): Trough Plasma Concentration, Lower Limit of Quantification (LLOQ)	Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (RT) (if occurs): RT Days 1-4; Follow-Up at Day 771	Pharmacokinetics trough plasma concentrations are provided on the pre-dose levels for the six patients enrolled.	ng/mL	MEAN
SECONDARY	Pharmacokinetics (PK): Maximum Plasma Concentrations (Cmax)	Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (if occurs): RT Days 1-4; Follow-Up at Day 771	The observed Cmax values on the 6 patients have been provided.	ng/mL	MEDIAN
SECONDARY	Pharmacokinetics (PK): Area Under Time-concentration Curve (AUC)	Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (if occurs): RT Days 1-4; Follow-Up at Day 771	PK modeling for calculating the AUC was not performed because the study was not completed.
SECONDARY	Pharmacodynamics (PD): Inhibition of C3 Activity (%)	Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (if occurs): RT Days 1-4; Follow-Up at Day 771	Any patient who received drug and measurable C3 activity.	Inhibition of C3 activity (%)	MEDIAN
SECONDARY	Pharmacodynamics (PD): Inhibition of C4 Activity (%)	Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (if occurs): RT Days 1-4; Follow-Up at Day 771	Any patient who received drug and measurable C4 activity.	Inhibition of C4 activity (%)	MEDIAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03205995/outcomes

API reference For AI assistants